Nuclear medicine imaging of neuroendocrine tumours.
作者信息
Al-Nahhas Adil
机构信息
Department of Nuclear Medicine, Hammersmith Hospital, Imperial College NHS Trust, London.
出版信息
Clin Med (Lond). 2012 Aug;12(4):377-80. doi: 10.7861/clinmedicine.12-4-377.
Abstract
摘要
相似文献
1
Nuclear medicine imaging of neuroendocrine tumours.
Clin Med (Lond). 2012 Aug;12(4):377-80. doi: 10.7861/clinmedicine.12-4-377.
2
Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?
Endocrine. 2012 Aug;42(1):3-4. doi: 10.1007/s12020-012-9681-4.
3
68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.
Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):724. doi: 10.1007/s00259-004-1697-4.
4
Should we stop offering indium-111 octreotide scans in favour of gallium-68 PET-CT scans in the UK?
Nucl Med Commun. 2016 Dec;37(12):1221-1222. doi: 10.1097/MNM.0000000000000596.
5
Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):466. doi: 10.1007/s00259-003-1436-2. Epub 2004 Jan 17.
6
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Eur J Nucl Med. 2001 Dec;28(12):1751-7. doi: 10.1007/s002590100639. Epub 2001 Oct 31.
7
Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
J Control Release. 2012 Jun 10;160(2):254-63. doi: 10.1016/j.jconrel.2011.12.038. Epub 2012 Jan 5.
8
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73. doi: 10.1677/ERC-09-0078. Print 2010 Mar.
9
Somatostatin receptor imaging: current status and future perspectives.
J Nucl Med. 2001 Jul;42(7):1057-8.
10
Gallium-68 PET: a new frontier in receptor cancer imaging.
Anticancer Res. 2007 Nov-Dec;27(6B):4087-94.
引用本文的文献
1
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.
J Neuroendocrinol. 2025 Mar;37(3):e13469. doi: 10.1111/jne.13469. Epub 2024 Nov 20.
2
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1965-1980. doi: 10.1007/s00259-024-06719-5. Epub 2024 Apr 27.
3
A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.
J Clin Med. 2023 Aug 5;12(15):5138. doi: 10.3390/jcm12155138.
4
Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
Medicine (Baltimore). 2023 May 12;102(19):e33726. doi: 10.1097/MD.0000000000033726.
5
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now.
Cancers (Basel). 2022 Feb 1;14(3):761. doi: 10.3390/cancers14030761.
6
Recurrent Adenomatous Neuroendocrine Tumor of the Middle Ear: A Diagnostic Challenge.
Case Rep Otolaryngol. 2018 Nov 25;2018:8619434. doi: 10.1155/2018/8619434. eCollection 2018.
7
Prospective of Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.
Contrast Media Mol Imaging. 2018 Jan 4;2018:9713691. doi: 10.1155/2018/9713691. eCollection 2018.
8
Prospective of ⁶⁸Ga-radiopharmaceutical development.
Theranostics. 2013 Dec 10;4(1):47-80. doi: 10.7150/thno.7447.
本文引用的文献
1
PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism.
PET Clin. 2007 Jul;2(3):351-75. doi: 10.1016/j.cpet.2008.04.007. Epub 2011 Oct 6.
2
⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S61-7. doi: 10.1007/s00259-011-1990-y.
3
Detection of unsuspected bone metastases by ⁶⁸Ga-DOTA: nuclear medicine at the forefront again.
Nucl Med Commun. 2011 Oct;32(10):877-9. doi: 10.1097/MNM.0b013e32834ad802.
4
68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
Mol Imaging Biol. 2011 Aug;13(4):769-75. doi: 10.1007/s11307-010-0396-8.
5
Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
J Nucl Med. 2009 Aug;50(8):1214-21. doi: 10.2967/jnumed.108.060236. Epub 2009 Jul 17.
6
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17.
7
68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
Nucl Med Commun. 2008 May;29(5):415-7. doi: 10.1097/MNM.0b013e3282ffd70d.
8
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469.
9
Gallium-68 PET: a new frontier in receptor cancer imaging.
Anticancer Res. 2007 Nov-Dec;27(6B):4087-94.
10
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
J Nucl Med. 2007 Apr;48(4):508-18. doi: 10.2967/jnumed.106.035667.
Zotero 插件